GSK confirmed it has reached a confidential settlement with James Goetz, and the case he filed in California state court, set to begin trial on July 24, 2023, will be dismissed. GSK said “The settlement reflects the Company’s desire to avoid distraction related to protracted litigation in this case. GSK does not admit any liability in this settlement and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases.”
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on GSK:
- GSK Rises after Reaching Settlement of Zantac Litigation
- PFE and GSK Stocks: RSV Vaccines Get Support from CDC Advisors
- GSK announces U.S. CDC AdCom votes to recommend Arexvy in RSV prevention
- GSK shares data for AREXVY, its RSV older adult vaccine
- GSK shares ‘positive data’ for RSV vaccine for older adults
